Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

BACKGROUND: NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors. METHODS: Patients received NIS793 (0.3–1 mg/kg every 3 weeks (Q3W)) monothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Todd M, Santoro, Armando, Lin, Chia-Chi, Garrido-Laguna, Ignacio, Joerger, Markus, Greil, Richard, Spreafico, Anna, Yau, Thomas, Goebeler, Maria-Elisabeth, Hütter-Krönke, Marie Luise, Perotti, Antonella, Juif, Pierre-Eric, Lu, Darlene, Barys, Louise, Cremasco, Viviana, Pelletier, Marc, Evans, Helen, Fabre, Claire, Doi, Toshikiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689375/
https://www.ncbi.nlm.nih.gov/pubmed/38030303
http://dx.doi.org/10.1136/jitc-2023-007353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689375/
https://www.ncbi.nlm.nih.gov/pubmed/38030303
http://dx.doi.org/10.1136/jitc-2023-007353

Ejemplares similares